Actavis Settles Intuniv Generic-Delay Claims for $1.1 Million

Teva Pharmaceutical Industries Ltd. unit Actavis Elizabeth LLC will pay $1.1 million to resolve consumer antitrust claims over its alleged role in a scheme to delay generic competition for Shire Plc’s attention deficit drug Intuniv, according to a federal court filing in Boston.

The “indirect purchaser” agreement, docketed Monday in the U.S. District Court for the District of Massachusetts, is the second by Actavis, which previously said it would pay $19.9 million to settle claims on behalf of “direct purchasers” like drug distributors.

The deals, which don’t require any admission of wrongdoing, also call for Actavis to cooperate against Shire. ...